Neuroprotective adeno‐associated virus Bcl‐xL gene transfer in models of motor neuron disease

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Muscle and Nerve

• Publication date

  2005-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/mus.20418PMID 16116646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Benefit of valproic acid in suppressing disease progression of ALS model mice

  2004cited by this paper
• Apoptosis and caspases in neurodegenerative diseases.

  2003cited by this paper
• Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery.

  2003cited by this paper
• Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model

  2003cited by this paper
• Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients.

  2002cited by this paper
• GLT-1 glutamate transporter levels are unchanged in mice expressing G93A human mutant SOD1.

  2002cited by this paper
• Control of cell survival by IGF signaling pathways.

  2002cited by this paper
• Ex vivo and in vitro studies of transgene expression in rat astrocytes transduced with lentiviral vectors.

  2002cited by this paper
• Adenosine deaminase gene therapy protocol revisited.

  2002cited by this paper
• Targeted retrograde gene delivery for neuronal protection.

  2002cited by this paper
• Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)

  2002cited by this paper
• Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.

  2001cited by this paper
• Recruitment of the Mitochondrial-Dependent Apoptotic Pathway in Amyotrophic Lateral Sclerosis

  2001cited by this paper
• Clinical Characteristics and Management of ALS

  2001cited by this paper
• How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot.

  2001cited by this paper
• Gene therapy against neurological insults: sparing neurons versus sparing function.

  2001cited by this paper
• Differences in survival‐promoting effects and intracellular signaling properties of BDNF and IGF‐1 in cultured cerebral cortical neurons

  2001cited by this paper
• Sparing of neuronal function postseizure with gene therapy.

  2000cited by this paper
• Delaying Caspase Activation by Bcl-2: A Clue to Disease Retardation in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

  2000cited by this paper
• Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2.

  2000cited by this paper
• Tropism of AAV‐2 vectors for neurons of the globus pallidus

  2000cited by this paper
• Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model.

  2000cited by this paper
• Progress in Adeno-Associated Virus Type 2 Vector Production: Promises and Prospects for Clinical Use

  1999cited by this paper
• The role of cell death in heart failure.

  1999cited by this paper
• Inhibition of caspases prevents cell death of hippocampal CA1 neurons, but not impairment of hippocampal long-term potentiation following global ischemia.

  1999cited by this paper
• Motor neuron degeneration is attenuated in bax‐deficient neurons in vitro

  1999cited by this paper
• Adenovirus-mediated gene transfer of Bcl-xL prevents cell death in primary neuronal culture of the rat.

  1999cited by this paper
• Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors

  1998cited by this paper
• Selective and Rapid Uptake of Adeno-Associated Virus Type 2 in Brain

  1998cited by this paper
• Glutamate uptake is decreased tardively in the spinal cord of FALS mice

  1998cited by this paper
• Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis.

  1997cited by this paper
• Inhibition of ICE slows ALS in mice

  1997cited by this paper
• Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease

  1996cited by this paper
• Motor Neuron Degeneration Induced by Excitotoxin Agonists Has Features in Common with those Seen in the SOD-1 Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

  1996cited by this paper
• Apoptosis, oncosis, and necrosis. An overview of cell death.

  1995cited by this paper
• In situ detection of fragmented dna (tunel assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note

  1995cited by this paper
• Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease

  1995cited by this paper
• Motor neuron disease caused by mutations in superoxide dismutase 1.

  1995cited by this paper
• Superoxide Dismutase Concentration and Activity in Familial Amyotrophic Lateral Sclerosis

  1995cited by this paper
• Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

  1995cited by this paper
• Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF.

  1994cited by this paper
• Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

  1994cited by this paper
• Topographic organization of embryonic motor neurons defined by expression of LIM homeobox genes.

  1994cited by this paper
• Evidence for autoimmunity in amyotrophic lateral sclerosis.

  1994cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

  1993cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

  1993cited by this paper
• Evidence for autoimmunity in amyotrophic lateral sclerosis.

  1993cited by this paper
• Early stages in the development of spinal motor neurons

  1992cited by this paper
• Differential expression of insulin-like growth factor-I and insulin-like growth factor binding protein-1 in the diabetic rat

  1991cited by this paper
• Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis

  1990cited by this paper
• Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics

  1972cited by this paper

• Evaluation of the SH-SY5Y cell line as an in vitro model for potency testing of a neuropeptide-expressing AAV vector

  2023cites this paper
• Acetylation state of RelA modulated by epigenetic drugs prolongs survival and induces a neuroprotective effect on ALS murine model

  2018cites this paper
• Control of mitochondrial physiology and cell death by the Bcl‐2 family proteins Bax and Bok

  2017cites this paper
• Gene Therapy for Amyotrophic Lateral Sclerosis

  2017cites this paper
• Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line.

  2016cites this paper
• The role of ALS associated genes and c-Jun in neurodegeneration

  2016cites this paper
• Gene Delivery and Therapy for Neurological Disorders

  2015cites this paper
• Adeno-Associated Viral Gene Therapy for Retinal Disorders

  2015cites this paper
• Tetradecanoylphorbol-13-acetate (TPA) significantly increases AAV2/5 transduction of human neuronal cells in vitro.

  2012cites this paper
• Gene and Cell Therapy for Peripheral Neuropathy

  2012cites this paper
• Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets

  2012cites this paper
• BCL2L1 (BCL-X) promotes survival of adult and developing retinal ganglion cells.

  2012cites this paper
• Gene therapy for amyotrophic lateral sclerosis.

  2012cites this paper
• Motor Neuron Diseases

  2011cites this paper
• Gene Therapy for Motor Neuron Disease

  2011cites this paper
• A new model to study spinal muscular atrophy: neurite degeneration and cell death is counteracted by BCL-X(L) Overexpression in motoneurons.

  2011cites this paper
• AAV-mediated expression of Bcl-xL or XIAP fails to induce neuronal resistance against quinolinic acid-induced striatal lesioning.

  2008cites this paper
• Drug therapy in amyotrophic lateral sclerosis.

  2008cites this paper
• Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro.

  2008cites this paper
• FUSION OF THE TETANUS TOXIN C FRAGMENT BINDING DOMAIN AND BCL‐XL FOR PROTECTION OF PERIPHERAL NERVE NEURONS

  2008cites this paper
• Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy.

  2008cites this paper
• Gene therapy for peripheral nervous system diseases.

  2007cites this paper
• Amyotrophic lateral sclerosis – The tools of the trait

  2007cites this paper
• Targeted Spinal Cord Therapeutics Delivery: Stabilized Platform and Microelectrode Recording Guidance Validation

  2007cites this paper
• AAV-vector mediated gene delivery for Huntington's Disease : an investigative therapeutic study.

  2007cites this paper
• Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders.

  2006cites this paper